These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15716212)

  • 1. Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84.
    Weston P; Persson BE
    Eur Urol; 2005 Mar; 47(3):422; author reply 422. PubMed ID: 15716212
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
    Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
    Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
    J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.
    Wagner M; Garzotto M; Lemmon D; Eilers KM; Beer TM
    Urology; 2005 Apr; 65(4):799. PubMed ID: 15833548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degarelix (firmagon) for prostate cancer.
    Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
    [No Abstract]   [Full Text] [Related]  

  • 6. [GnRH antagonists--a new therapy option for advanced prostate cancer].
    Wolff JM
    Aktuelle Urol; 2009 May; 40(3):159-63. PubMed ID: 19399720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
    van Poppel H; Nilsson S
    Urology; 2008 Jun; 71(6):1001-6. PubMed ID: 18407326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
    Weckermann D; Harzmann R
    Eur Urol; 2004 Sep; 46(3):279-83; discussion 283-4. PubMed ID: 15306097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Noel W. Clarke, Michael Marberger. The motion: GnRH antagonists are the new way forward in hormonal therapy. Eur Urol 2010;57:534-7.
    Drewa TA; Chlosta PL
    Eur Urol; 2010 Aug; 58(2):e20. PubMed ID: 20427120
    [No Abstract]   [Full Text] [Related]  

  • 11. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
    Pfitzenmaier J; Altwein JE
    Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment approaches for prostate cancer based on peptide analogues.
    Stangelberger A; Schally AV; Djavan B
    Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
    Usami M; Akaza H; Arai Y; Hirano Y; Kagawa S; Kanetake H; Naito S; Sumiyoshi Y; Takimoto Y; Terai A; Yoshida H; Ohashi Y
    Prostate Cancer Prostatic Dis; 2007; 10(2):194-201. PubMed ID: 17199134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of advanced prostate cancer: gonadotropin-releasing hormone blockers might improve prognosis.
    Heidenreich A
    Eur Urol; 2008 Oct; 54(4):726-7. PubMed ID: 18524468
    [No Abstract]   [Full Text] [Related]  

  • 18. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
    Miller K
    MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of a patient with locally advanced prostate cancer with degarelix: a case report.
    Ruzhynsky V; Whelan P
    Can J Urol; 2013 Jun; 20(3):6808-10. PubMed ID: 23783053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer: making the switch from LHRH antagonist to LHRH agonist.
    Moul JW
    Nat Rev Urol; 2012 Jan; 9(3):125-6. PubMed ID: 22289702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.